MorphoSys AG is a Germany-based biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies, with a primary emphasis on oncology and immunology. Originally known for its antibody technology, the company has built expertise in monoclonal and bispecific antibodies and targeted protein engineering.
Headquartered in Planegg near Munich, MorphoSys advances a pipeline of targeted cancer therapies and collaborates widely with pharmaceutical partners. Its marketed product tafasitamab (commercialized as Monjuvi/Minjuvi in collaboration with Incyte) is approved for certain patients with diffuse large B-cell lymphoma. The company continues to pursue late-stage programs, including small-molecule and epigenetic approaches, to address unmet medical needs in hematology and oncology.
Thomas Biegi, with a strong background in pharma and biotech communications, will succeed Nina Schwab-Hautzinger in April 2026, reporting to Markus Kamieth.
